Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2026-02-25 @ 4:15 AM
Study NCT ID:
NCT03028103
Status:
COMPLETED
Last Update Posted:
2023-06-26
First Post:
2016-12-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Sponsor:
Epizyme, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
EZH-105
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None